文献速递临床试验与 GCP

WONDER-01:超声内镜引导下包裹性坏死引流后即刻坏死清除术对比引流导向的升阶梯策略——多中心随机对照试验研究方案

WONDER-01: immediate necrosectomy vs. drainage-oriented step-up approach after endoscopic ultrasound-guided drainage of walled-off necrosis-study protocol for a multicentre randomised controlled trial.
PubMed 文献 · Trials · 2023-05-24

WONDER-01是一项在日本23个中心开展的多中心、开放标签、优效性随机对照试验,计划纳入70例需超声内镜引导治疗的包裹性坏死患者,按1:1随机分为即刻直接内镜下坏死清除术组和引流导向的升阶梯策略组,主要终点为临床成功时间,旨在比较两种策略的疗效与安全性。

要点

  • WONDER-01为多中心、开放标签、优效性随机对照试验,计划在日本23个中心纳入70例包裹性坏死患者。
  • 患者按1:1随机接受即刻直接内镜下坏死清除术或引流导向的升阶梯策略,每组35例。
  • 主要终点为临床成功时间,定义为包裹性坏死缩小至≤3 cm且炎症标志物改善。

核心结论

  • WONDER-01试验将探讨即刻直接内镜下坏死清除术对比升阶梯策略在接收超声内镜引导治疗的包裹性坏死患者中的疗效与安全性,研究结果将有助于为有症状的包裹性坏死患者建立新的治疗标准。

研究设计与样本

  • 多中心、开放标签、优效性、随机对照试验,计划在日本23个中心纳入70例年龄≥18岁、需超声内镜引导治疗的包裹性坏死患者,按1:1随机分为即刻直接内镜下坏死清除术组和引流导向的升阶梯策略组,每组35例。

主要发现

  • 即刻直接内镜下坏死清除术组在超声内镜引导下引流时或引流后72小时内开始直接内镜下坏死清除术。
  • 升阶梯策略组在72至96小时观察后考虑以引流为基础的升阶梯治疗并按需行直接内镜下坏死清除术。
  • 主要终点为临床成功时间,临床成功定义为包裹性坏死缩小至≤3 cm且炎症标志物(体温、白细胞计数和C反应蛋白)改善。
  • 次要终点包括技术成功、包括死亡率在内的不良事件以及包裹性坏死复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: With the increasing popularity of endoscopic ultrasound (EUS)-guided transmural interventions, walled-off necrosis (WON) of the pancreas is increasingly managed via non-surgical endoscopic interventions. However, there has been an ongoing debate over the appropriate treatment strategy following the initial EUS-guided drainage. Direct endoscopic necrosectomy (DEN) removes intracavity necrotic tissue, potentially facilitating early resolution of the WON, but may associate with a high rate of adverse events. Given the increasing safety of DEN, we hypothesised that immediate DEN following EUS-guided drainage of WON might shorten the time to WON resolution compared to the drainage-oriented step-up approach. METHODS: The WONDER-01 trial is a multicentre, open-label, superiority, randomised controlled trial, which will enrol WON patients aged ≥ 18 years requiring EUS-guided treatment in 23 centres in Japan. This trial plans to enrol 70 patients who will be randomised at a 1:1 ratio to receive either the immediate DEN or drainage-oriented step-up approach (35 patients per arm). In the immediate DEN group, DEN will be initiated during (or within 72 h of) the EUS-guided drainage session. In the step-up approach group, drainage-based step-up treatment with on-demand DEN will be considered after 72-96 h observation. The primary endpoint is time to clinical success, which is defined as a decrease in a WON size to ≤ 3 cm and an improvement of inflammatory markers (i.e. body temperature, white blood cell count, and C-reactive protein). Secondary endpoints include technical success, adverse events including mortality, and recurrence of the WON. DISCUSSION: The WONDER-01 trial will investigate the efficacy and safety of immediate DEN compared to the step-up approach for WON patients receiving EUS-guided treatment. The findings will help us to establish new treatment standards for patients with symptomatic WON. TRIAL REGISTRATION: ClinicalTrials.gov NCT05451901, registered on 11 July 2022. UMIN000048310, registered on 7 July 2022. jRCT1032220055, registered on 1 May 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sato T, Saito T, Takenaka M, et al. WONDER-01: immediate necrosectomy vs. drainage-oriented step-up approach after endoscopic ultrasound-guided drainage of walled-off necrosis-study protocol for a multicentre randomised controlled trial. Trials. 2023. PMID: 37226252. doi:10.1186/s13063-023-07377-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。